Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, discuss key data supporting contemporary dosing strategies with the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:
GI Medical Oncology
University of Texas MD Anderson Cancer Center
Director, Clinical Oncology
AC Camargo Cancer Center
Sao Paulo, Brazil
This program has been made available online.
Expert commentary on potential clinical implications of findings from the MOUNTAINEER trial with tucatinib and trastuzumab in HER2 positive metastatic colorectal cancer, from Clinical Care Options (CCO)
Nina Beri, MD reviews ongoing clinical trials in targeted therapies for patients with cholangiocarcinoma presented at ASCO 2022, from Clinical Care Options (CCO)
Downloadable slideset on therapies for previously treated advanced HER2-negative gastric/GEJ cancers, from Clinical Care Options (CCO)
Downloadable clinical resource with practical guidance on how to talk with your transgender patients about gender identity, including related terminology, from Clinical Care Options (CCO)